Comparative Pharmacology
Head-to-head clinical analysis: MAXAIR versus POLMON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXAIR versus POLMON.
MAXAIR vs POLMON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular cAMP.
Polmon (polymyxin B) is a cationic polypeptide antibiotic that disrupts bacterial cell membrane integrity by binding to lipopolysaccharides and phospholipids in the outer membrane, increasing permeability and causing cell death.
2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.
1-2 mg intravenously every 2-4 hours as needed; maximum 8 mg/day.
None Documented
None Documented
3.5–4.0 hours; clinically, this supports dosing every 4–6 hours as needed.
Terminal elimination half-life is 12-18 hours in healthy adults; prolonged to 24-36 hours in severe hepatic impairment requiring dose adjustment.
Renal excretion of unchanged drug accounts for approximately 90% of elimination; fecal excretion is minimal (<5%).
Renal excretion of unchanged drug accounts for 40-50% of elimination; biliary/fecal excretion accounts for 50-60%.
Category C
Category C
Bronchodilator
Bronchodilator